RetinalGenix Technologies Inc. (RTGN)

USD 53.0

(88.0%)

Long Term Debt Summary of RetinalGenix Technologies Inc.

  • RetinalGenix Technologies Inc.'s latest annual long term debt in 2023 was - USD , down 0.0% from previous year.
  • RetinalGenix Technologies Inc.'s latest quarterly long term debt in 2024 Q2 was - USD , down 0.0% from previous quarter.
  • RetinalGenix Technologies Inc. reported annual long term debt of - USD in 2022, down 0.0% from previous year.
  • RetinalGenix Technologies Inc. reported annual long term debt of - USD in 2021, down 0.0% from previous year.
  • RetinalGenix Technologies Inc. reported quarterly long term debt of - USD for 2024 Q1, down 0.0% from previous quarter.
  • RetinalGenix Technologies Inc. reported quarterly long term debt of - USD for 2023 Q2, down 0.0% from previous quarter.

Annual Long Term Debt Chart of RetinalGenix Technologies Inc. (2023 - 2018)

Historical Annual Long Term Debt of RetinalGenix Technologies Inc. (2023 - 2018)

Year Long Term Debt Long Term Debt Growth
2023 - USD 0.0%
2022 - USD 0.0%
2021 - USD 0.0%
2020 - USD 0.0%
2019 - USD 0.0%
2018 - USD 0.0%

Peer Long Term Debt Comparison of RetinalGenix Technologies Inc.

Name Long Term Debt Long Term Debt Difference
Acutus Medical, Inc. 32.65 Million USD 100.0%
Biotricity, Inc. 10.85 Million USD 100.0%
Cell MedX Corp. - USD NaN%
Dynatronics Corporation 3.25 Million USD 100.0%
Nemaura Medical Inc. 3.08 Million USD 100.0%
PetVivo Holdings, Inc. 1.01 Million USD 100.0%
Sonendo, Inc. 14.03 Million USD 100.0%
Telesis Bio, Inc. 5.26 Million USD 100.0%
Talis Biomedical Corporation 16.78 Million USD 100.0%
Viveve Medical, Inc. 5.12 Million USD 100.0%